Business Wire

THALES

Share
2024 Thales Data Threat Report Reveals Rise in Ransomware Attacks, as Compliance Failings Leave Businesses Vulnerable to Breaches

Thales today announced the release of the 2024 Thales Data Threat Report, its annual report on the latest data security threats, trends, and emerging topics based on a survey of nearly 3000 IT and security professionals in 18 countries across 37 industries. This year’s report found that 93% of IT professionals believe security threats are increasing in volume or severity, a significant rise from 47% last year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320217738/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

Threats continue to increase in volume and severity

The number of enterprises experiencing ransomware attacks surged by over 27% in the past year. Despite this escalating threat, less than half of organisations have a formal ransomware plan in place, with 8% resorting to paying the ransom demands.

Malware stands out as the fastest-growing threat of 2024, with 41% of enterprises witnessing a malware attack in the past year – closely followed by phishing and ransomware. Cloud assets, including SaaS applications, cloud-based storage, and cloud infrastructure management, remain the primary targets for such attacks.

The report shows that for a second year running, human error remains the leading cause of data breaches, with 31% of enterprises pinpointing this as the root cause.

These insights are drawn from the 2024 Thales Data Threat Report, conducted by 451 Research. The report sheds light on how businesses are adapting their data security strategies and practices in response to an evolving threat landscape.

Compliance is the key to data security

The research found that over two fifths (43%) of enterprises failed a compliance audit in the past twelve months – with the report highlighting a very clear correlation between compliance and data security.

Of those that had failed a compliance audit in the past twelve months, 31% had experienced a breach that very same year. This compares to just 3% of those who had passed compliance audits.

Operational complexity continues to cause data headaches

Fundamental understanding of what systems, applications, and data are at risk continue to lag due to changing regulatory and threat landscapes. Only a third (33%) of organisations are able to fully classify all of their data, with a worrying 16% stating that they classify very little or none of their data.

Operational complexity remains a barrier. While the number of respondents reporting five or more key management systems is down (53% versus 62% last year), the average number declined only slightly (from 5.6 to 5.4).

The reality of multicloud across services and changing global data privacy regulations means that data sovereignty is a leading priority for businesses, with 28% identifying mandatory external key management as the leading way to achieve sovereignty. 39% said that data residency would no longer be an issue provided that external encryption, key management, and separation of duties were implemented.

“Enterprises need to know exactly what they’re trying to protect. With global data privacy regulations continually changing, they need to have good visibility across their organization to stand any chance of staying compliant,” said Sebastien Cano, Senior Vice President at Thales Cloud Protection and Licensing.

“If there’s one key takeaway from this year’s study, it’s that compliance is key. In fact, companies that had a good hold over their compliance processes and passed all their audits were also less likely to suffer a breach. We’ll start to see more compliance and security functions coming together. This would be a huge positive step to strengthen cyber defenses and build trust with customers,” he added.

Emerging technology poses both threats and opportunities

Looking ahead, the report also explored which emerging technologies are top-of-mind for IT and security professionals, with 57% identifying Artificial Intelligence (AI) as a huge source of concern. This was closely followed by IoT (55%) and Post Quantum Cryptography (45%).

That said, enterprises are also looking at the opportunities that emerging technologies bring, with over a fifth (22%) planning to integrate Generative AI into their security products and services in the next 12 months, and a third (33%) planning to experiment integrating the technology.

For more information please join our webinar with S&P Global on April 16, 2024 hosted by Eric Hanselman, Chief Analyst and Justin Lam, Research Analyst.

About the 2024 Thales Global Data Threat Report
The 2024 Data Threat Report (DTR) analyzes how core security practices have changed in response to or in anticipation of changing threats. This report also offers perspectives on what organizations can do to leverage data assets to expand opportunities to make their businesses more agile and build trust with their customers. This research was based on a global survey of 2,961 respondents fielded via web survey with targeted populations for each country, aimed at professionals in security and IT management. In addition to criteria about level of knowledge on the general topic of the survey, the screening criteria for the survey excluded those respondents who indicated affiliation with organizations with annual revenue of less than US$100 million and with US$100 million-$250 million in Australia, Brazil, Canada, France, Germany, Hong Kong, India, Italy, Japan, Mexico, the Netherlands, New Zealand, South Korea, Singapore, Sweden, the United Arab Emirates, the United Kingdom and the United States of America.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

* These figures exclude the ground transportation business, which is being divested

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240320217738/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e

AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release

Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its

Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release

4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye